UBS Group AG raised its position in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 28.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 662,317 shares of the company’s stock after purchasing an additional 147,389 shares during the quarter. UBS Group AG’s holdings in Twist Bioscience were worth $21,009,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Quarry LP bought a new position in Twist Bioscience in the 3rd quarter valued at approximately $28,000. Smartleaf Asset Management LLC grew its holdings in Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after acquiring an additional 442 shares during the last quarter. National Bank of Canada FI bought a new stake in Twist Bioscience during the 3rd quarter worth approximately $46,000. Mirae Asset Global Investments Co. Ltd. increased its position in Twist Bioscience by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,971 shares of the company’s stock valued at $94,000 after acquiring an additional 637 shares during the period. Finally, Geneos Wealth Management Inc. bought a new position in shares of Twist Bioscience during the second quarter valued at $97,000.
Analyst Ratings Changes
A number of brokerages have recently commented on TWST. Barclays lifted their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Evercore lifted their target price on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. Leerink Partners upgraded Twist Bioscience from a “market perform” rating to an “outperform” rating and set a $70.00 price target on the stock in a research report on Tuesday, May 5th. Finally, Guggenheim increased their price target on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $56.57.
Twist Bioscience Price Performance
TWST stock opened at $56.21 on Tuesday. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. The company’s fifty day simple moving average is $51.35 and its 200 day simple moving average is $41.98. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $66.06. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of -42.26 and a beta of 2.22.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The business had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s revenue was up 19.3% on a year-over-year basis. During the same period last year, the business posted ($0.66) earnings per share. On average, analysts expect that Twist Bioscience Corporation will post -1.86 earnings per share for the current year.
Insider Transactions at Twist Bioscience
In other Twist Bioscience news, Director Robert Chess sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total transaction of $470,000.00. Following the transaction, the director directly owned 21,084 shares in the company, valued at approximately $990,948. This represents a 32.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Melissa A. Starovasnik sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total transaction of $51,000.00. Following the sale, the director directly owned 25,722 shares of the company’s stock, valued at approximately $1,311,822. This trade represents a 3.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 46,551 shares of company stock valued at $2,492,743. 3.08% of the stock is owned by insiders.
Twist Bioscience Profile
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Read More
- Five stocks we like better than Twist Bioscience
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
